Warning: Undefined variable $page_cluster_id in /home3/thegood9/public_html/website_70aad9ea/header.php on line 29



Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Tag Directory / HEALTHCAREFINANCE     showing 1–5 of 5   RSS


for: Saturday, May 09, 2026



A new Medicare option for weight loss drugs is coming: Here's what to know

Jackie Fortiér / npr - Millions of people with Medicare will soon be eligible to get discounted GLP-1 drugs for weight loss. Here's how it will work.

AI Summary: Medicare is introducing a new option to expand access to weight‑loss medications for older Americans, outlining eligibility, coverage mechanics and likely impacts on beneficiaries and budgets. The guidance aims to help clinicians and patients navigate coverage decisions and prepares stakeholders for shifts in prescribing patterns and costs as demand for GLP‑1 class drugs remains high.


Competition, dosing and long-term weight strategies

19 days / bbc


Efficacy and safety of GLP‑1s in older adults

21 days / medicalxpress

21 days / medicalxpress


Medicare expansion and coverage landscape


All Other Stories

14 days / medicalxpress

15 days / medicalxpress

16 days / medicalxpress

16 days / medicalxpress

16 days / medicalxpress

16 days / medicalxpress

16 days / medicalxpress

17 days / medicalxpress

17 days / medicalxpress

17 days / medicalxpress

17 days / medicalxpress

18 days / medicalxpress

18 days / medicalxpress

18 days / bbc

18 days / oncodaily

19 days / medicalxpress

20 days / medicalxpress

21 days / medicalxpress



UCB bets $2 billion on Candid's T cell engager ambitions

Kyle LaHucik / endpoints - Ken Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies. UCB is paying $2 ...

AI Summary: UCB has struck a roughly $2 billion deal to acquire Candid, betting heavily on Candid’s T‑cell engager platform to reset immune‑based oncology programs. The acquisition boosts UCB’s immuno‑oncology pipeline and signals intensified competition in T‑cell engager development, with investors and researchers watching closely to see how science translates into clinical wins.

#pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment #oncology #healthcarefinance #cancerresearch #clinicaltrials

14 days / oncodaily

16 days / newscientist

18 days / oncodaily

19 days / medicalxpress

20 days / oncodaily

21 days / oncodaily

21 days / oncodaily


Back to Top / Saturday, May 9, 2026, 8:21 am / permalink 23511 / 9 stories in 22 days /

Sanford Health unveils deal to integrate Minnesota-area North Memorial Health, invest $600M

fiercehealthcare - The deal, expected to close later this year, is another attempt from the major rural nonprofit system to enter the Minneapolis market. To do so, it plans a $600 million investment into two-hospital North Memorial Health that will help stabilize one financ…

AI Summary: Sanford Health announced a plan to integrate Minnesota-area North Memorial Health with a $600 million investment, creating a combined system aimed at expanding services, streamlining care and gaining scale. The transaction is part of a broader wave of regional healthcare consolidation as systems chase efficiency and market presence.

#healthcare #mergersandacquisitions #corporatetakeover #hospitaloperations #healthcarefinance

Back to Top / Saturday, May 9, 2026, 12:21 am / permalink 23483 / 10 stories in 22 days /

Staffing firm Cross Country Healthcare to be acquired by Knox Lane for $437M

fiercehealthcare - The deal would bring the 40-year-old, publicly traded company under a growth-oriented investment firm with a prior background in healthcare staffing.

AI Summary: Staffing firm Cross Country Healthcare agreed to be taken private in a $437 million deal by private equity buyer Knox Lane, ending its public-company chapter. The acquisition positions the firm for strategic repositioning and could reverberate across hospital staffing markets as investors consolidate workforce services.

#healthcare #mergersandacquisitions #corporatetakeover #hospitaloperations #healthcarefinance #venturecapital

Back to Top / Saturday, May 9, 2026, 12:21 am / permalink 23484 / 4 stories in 22 days /

Amwell expects smaller losses in 2026 after Q1 performance

Emily Olsen / healthcaredive - The health technology firm’s results give Amwell “increased confidence” it will meet a long-term goal of achieving positive cash flow from operations in the fourth quarter, CFO Mark Hirschhorn said.

AI Summary: Telehealth provider Amwell posted Q1 results showing better-than-expected customer renewals and retention, helping the company forecast smaller losses despite soft revenue. The results suggest operational improvements are stabilizing the business and give investors a slightly less gloomy view of the telehealth market's near-term prospects.

#healthcare #digitalhealth #healthcarefinance #telemedicine #healthit

20 days / medicalxpress


Back to Top / Saturday, May 9, 2026, 12:21 am / permalink 23487 / 5 stories in 22 days /

Back to Top


HEALTHCAREFINANCE Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.


StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Corporate Takeover, Oncology, Rural Health, Supplements and look for the RSS link.


NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.